BR112023002248A2 - Inibidores de quinase e usos dos mesmos - Google Patents

Inibidores de quinase e usos dos mesmos

Info

Publication number
BR112023002248A2
BR112023002248A2 BR112023002248A BR112023002248A BR112023002248A2 BR 112023002248 A2 BR112023002248 A2 BR 112023002248A2 BR 112023002248 A BR112023002248 A BR 112023002248A BR 112023002248 A BR112023002248 A BR 112023002248A BR 112023002248 A2 BR112023002248 A2 BR 112023002248A2
Authority
BR
Brazil
Prior art keywords
compounds
methods
kinase
kinase inhibitors
compositions
Prior art date
Application number
BR112023002248A
Other languages
English (en)
Portuguese (pt)
Inventor
Chen Chen
Original Assignee
Abm Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abm Therapeutics Corp filed Critical Abm Therapeutics Corp
Publication of BR112023002248A2 publication Critical patent/BR112023002248A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112023002248A 2020-08-07 2021-08-06 Inibidores de quinase e usos dos mesmos BR112023002248A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063063113P 2020-08-07 2020-08-07
PCT/US2021/044907 WO2022032071A1 (en) 2020-08-07 2021-08-06 Kinase inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
BR112023002248A2 true BR112023002248A2 (pt) 2023-03-07

Family

ID=77711412

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023002248A BR112023002248A2 (pt) 2020-08-07 2021-08-06 Inibidores de quinase e usos dos mesmos

Country Status (10)

Country Link
US (1) US20230303570A1 (https=)
EP (1) EP4192582A1 (https=)
JP (1) JP2023538521A (https=)
KR (1) KR20230112605A (https=)
CN (1) CN116710453A (https=)
AU (1) AU2021321536A1 (https=)
BR (1) BR112023002248A2 (https=)
CA (1) CA3179671A1 (https=)
MX (1) MX2023001312A (https=)
WO (1) WO2022032071A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4577546A1 (en) * 2022-08-25 2025-07-02 Enliven Inc. Naphthyridine compounds for inhibition of raf kinases
WO2024199388A1 (zh) * 2023-03-29 2024-10-03 微境生物医药科技(上海)有限公司 作为myt1抑制剂的化合物
WO2025064567A1 (en) * 2023-09-19 2025-03-27 Enliven Inc. Tricyclic phenols for inhibition of raf kinases
WO2025152919A1 (en) * 2024-01-15 2025-07-24 Impact Therapeutics (Shanghai) , Inc. Crystal forms of a weel inhibitor and preparation method thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503802A (ja) * 2002-04-03 2006-02-02 エフ．ホフマン−ラ　ロシュ　アーゲー イミダゾ縮合化合物
EP2348020A1 (en) 2009-12-23 2011-07-27 Esteve Química, S.A. Preparation process of erlotinib
FR2974088A1 (fr) * 2011-04-12 2012-10-19 Pf Medicament Composes pyrazolo[3,4-b]pyridines tri- et tetracycliques comme agent anticancereux
RU2019102647A (ru) * 2016-07-01 2020-08-03 Г1 Терапьютикс, Инк. Антипролиферационные средства на основе пиримидина
EP3684772B1 (en) * 2017-09-20 2023-12-06 ABM Therapeutics Corporation Cyclic iminopyrimidine derivatives as kinase inhibitors
CN110950867A (zh) * 2018-09-27 2020-04-03 首药控股(北京)有限公司 一种fgfr4激酶抑制剂及其制备方法和用途

Also Published As

Publication number Publication date
CA3179671A1 (en) 2022-02-10
KR20230112605A (ko) 2023-07-27
EP4192582A1 (en) 2023-06-14
JP2023538521A (ja) 2023-09-08
CN116710453A (zh) 2023-09-05
WO2022032071A1 (en) 2022-02-10
MX2023001312A (es) 2023-04-12
AU2021321536A1 (en) 2023-03-09
US20230303570A1 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
BR112023002248A2 (pt) Inibidores de quinase e usos dos mesmos
ECSP22029193A (es) Aminas bicíclicas como inhibidoras de la cdk2
MX387394B (es) Compuestos heterociclicos como inhibidores de la cinasa ret.
EP4523755A3 (en) Quinazoline derivatives as antitumor agents
MX382354B (es) Compuestos heterocíclicos y usos de los mismos.
MX389700B (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
EA201492176A1 (ru) Селективные ингибиторы pi3k дельта
MX2022007130A (es) Derivados de piperazina sustituidos utiles como activadores de celulas t.
PH12017500146B1 (en) 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
SA522441624B1 (ar) مثبطات إنزيمات كيناز مستقبل عامل نمو الأرومة الليفية
BR112017005531A2 (pt) derivados de diaril ureia como inibidores de quinase p38
MX346183B (es) Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas heteroarilo-sustituidas como inhibidores de cinasas janus.
MD4735B1 (ro) Derivaţi ai pirolo[2,3-d]pirimidinei ca inhibitori de Kinaze Janus-asociate (JAK)
MX2022008627A (es) Pirazolo-pirimidinas sustituidas y usos de las mismas.
UA113156C2 (xx) Циклобутилзаміщені похідні піролопіридину й піролопіримідину як інгібітори jak
UY27811A1 (es) 3-aminopirazoles n-sustituidos como inhibidores para el tratamiento de los desórdenes proliferativos de las células.
MX2025001108A (es) Inhibidores de cinasas aminoheteroarílicos.
MX2024001202A (es) Derivados de heteroarilos biciclicos como inhibidores de ectonucleotido pirofosfatasa fosfodiesterasa 1
EA202192093A1 (ru) Пиразолопиридины и триазолопиридины в качестве ингибиторов a2а/a2b
BR112021019125A2 (pt) Inibidores de prmt5 e usos dos mesmos
JOP20240266A1 (ar) مركبات تريازولو ثلاثية الحلقة كمثبطات dgk
NZ630580A (en) 6-(4-(1-amino-3-hydroxycyclobutyl)phenyl)-5-phenyl(furo,thieno or pyrrolo) [2, 3-d] pyrimidin-4-one derivatives for the treatment of cancer
AR132251A1 (es) Derivados de 5-amino-6,8-dihidro-1h-furo[3,4-d]pirrolo[3,2-b]piridin-2-carboxamida como inhibidores cooperativos con mta de prmt5
MX376059B (es) Compuestos de pirimidina substituidos y su uso como inhibidores de la tirosina cinasa del bazo (syk).
CL2024003269A1 (es) Compuestos de 6-(pirimidin-4-il)quinolina sustituidos como inhibidores de la cinasa dependiente de ciclina